• Explore /
  • Poster
  • / Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

Abstract Video & Slides Poster

Authors

null

Oleh Kobziev

Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, Ukraine

Oleh Kobziev , Iurie Bulat , Yuriy Ostapenko , Zanete Zvirbule , Grygorii Ursol , Vasyl Boyko , Viktor Paramonov , Yasmin Hashambhoy-Ramsay , Courtney Hart , Christopher Harvey , Ashley Graca , Lidya Le , Weidong Zhang , Bo Chao , Judy Jimenez , Krithi Bala , Sarah Maxwell , Haley Laken , Johan Baeck , Ellen Michelle Diament Hooper

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04549025

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS9137)

DOI

10.1200/JCO.2021.39.15_suppl.TPS9137

Abstract #

TPS9137

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Timothy A Yap

First Author: Jared Cohen

First Author: Ze-Rui Zhao

First Author: Linlin Xu